Rita D'Ascenzo1, Sara Savini2, Chiara Biagetti2, Maria P Bellagamba2, Paolo Marchionni2, Adriana Pompilio2, Paola E Cogo3, Virgilio P Carnielli2. 1. Division of Neonatology, Department of Clinical Sciences, Polytechnic University of Marche and Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy. Electronic address: rita.dascenzo@gmail.com. 2. Division of Neonatology, Department of Clinical Sciences, Polytechnic University of Marche and Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy. 3. DMCCP, Pediatric Hospital "Bambino Gesù", Rome, Italy.
Abstract
BACKGROUND & AIMS:Lipid emulsions containing fish oil, as source of long chain omega 3 fatty acids, have recently became available for parenteral nutrition in infants, but scanty data exist in extremely low birth weight preterms. The objective of this study was to compare plasma fatty acids and lipid tolerance in preterm infants receiving different doses of a 15% fish oil vs. a soybean oil based lipid emulsion. METHODS:Preterm infants (birth weight 500-1249 g) were randomized to receive parenteral nutrition with MOSF (30% Medium-chain triglycerides, 25% Olive oil, 30% Soybean oil, 15% Fish oil) or S (S, 100% Soybean oil) both at two levels of fat intake: 2.5 or 3.5 g kg(-1) d(-1), named 2.5Fat and 3.5Fat respectively. Plasma lipid classes and their fatty acid composition were determined on postnatal day 7 and 14 by gas chromatography together with routine biochemistry. RESULTS: We studied 80 infants. MOSF infants had significantly higher plasma phospholipid Docosahexaenoic acid and Eicosapentaenoic and lower Arachidonic acid. Plasma phospholipids, triglycerides and free cholesterol were all significantly higher in the MOSF-3.5Fat group, while cholesterol esters were lower with MOSF than with S. The area under the curve of total bilirubin was significantly lower with MOSF than with S. CONCLUSIONS: The use of a lipid emulsion with 15% FO resulted in marked changes of plasma long-chain fatty acids. Whether the benefits of increasing Docosahexaenoic acid outweigh the potential negative effect of reduced Arachidonic acid should be further studied. MOSF patients exhibited reduced lipid tolerance at 3.5 g kg(-1) d(-1) fat intake. The trial was conducted between January 2008 and December 2012 so we had not registered it in a public trials registry as it is now required for trials that started after July 2008.
RCT Entities:
BACKGROUND & AIMS:Lipid emulsions containing fish oil, as source of long chain omega 3 fatty acids, have recently became available for parenteral nutrition in infants, but scanty data exist in extremely low birth weight preterms. The objective of this study was to compare plasma fatty acids and lipid tolerance in preterm infants receiving different doses of a 15% fish oil vs. a soybean oil based lipid emulsion. METHODS: Preterm infants (birth weight 500-1249 g) were randomized to receive parenteral nutrition with MOSF (30% Medium-chain triglycerides, 25% Olive oil, 30% Soybean oil, 15% Fish oil) or S (S, 100% Soybean oil) both at two levels of fat intake: 2.5 or 3.5 g kg(-1) d(-1), named 2.5Fat and 3.5Fat respectively. Plasma lipid classes and their fatty acid composition were determined on postnatal day 7 and 14 by gas chromatography together with routine biochemistry. RESULTS: We studied 80 infants. MOSFinfants had significantly higher plasma phospholipidDocosahexaenoic acid and Eicosapentaenoic and lower Arachidonic acid. Plasma phospholipids, triglycerides and free cholesterol were all significantly higher in the MOSF-3.5Fat group, while cholesterol esters were lower with MOSF than with S. The area under the curve of total bilirubin was significantly lower with MOSF than with S. CONCLUSIONS: The use of a lipid emulsion with 15% FO resulted in marked changes of plasma long-chain fatty acids. Whether the benefits of increasing Docosahexaenoic acid outweigh the potential negative effect of reduced Arachidonic acid should be further studied. MOSFpatients exhibited reduced lipid tolerance at 3.5 g kg(-1) d(-1) fat intake. The trial was conducted between January 2008 and December 2012 so we had not registered it in a public trials registry as it is now required for trials that started after July 2008.
Authors: Xue Fan; Ying Tang; Jun Tang; Juan Chen; Jing Shi; Hua Wang; Bin Xia; Yi Qu; Dezhi Mu Journal: J Perinatol Date: 2020-07-07 Impact factor: 2.521
Authors: Olajumoke Akinsulire; George Perides; Lorenzo Anez-Bustillos; Joanne Cluette-Brown; Arthur Nedder; Elizabeth Pollack; Pratibha Singh; Yan Liu; Lady Leidy Sanchez-Fernandez; Evelyn Obregon; Ece Bicak; Savanna Kiefer; William Yakah; Hilda V Gutierrez; Duy T Dao; Mustafa Vurma; Stefan Ehling; Douglas Gordon; Stephen DeMichele; Steven D Freedman; Camilia R Martin Journal: JPEN J Parenter Enteral Nutr Date: 2019-08-23 Impact factor: 4.016
Authors: Tiffany L Molina; Barbara Stoll; Mahmoud Mohammad; Carrie A Mohila; Lee Call; Liwei Cui; Gregory Guthrie; Dennis Kunichoff; Sen Lin; Rebecca Welch-Jernigan; Jon Nielsen; Muralidhar Premkumar; Jason Robinson; Victoria Smith; Haley Teets; Karina Obelitz-Ryom; Joseph Hagan; Stephanie Cruz; Patricio Lau; Maurice Puyau; Roman Shypailo; Rodrigo Manjarin; Nancy Butte; Zhengfeng Fang; Oluyinka Olutoye; Thomas Thymann; Per Sangild; Douglas Burrin Journal: Brain Behav Immun Date: 2019-04-24 Impact factor: 7.217